ICU获得性肌无力患者早期全身炎症反应增强:一项前瞻性观察性队列研究
该研究为荷兰一家三级医院混合内外科ICU的前瞻性观察性队列研究,纳入机械通气≥48小时且非神经科入ICU诊断的新入ICU危重患者204例,其中99例发生ICU获得性肌无力。在入ICU第0、2、4天检测血浆全身炎症标志物及可溶性血管黏附分子。校正混杂因素后,主成分回归分析显示以IL-6、IL-8、IL-10和fractalkine为主负载的主成分1在发生ICU获得性肌无力患者中显著更高(OR 1.35,95%CI 1.18-1.55),混合效应模型显示这些标志物独立升高1.5至2倍。提示ICU获得性肌无力发生与早期全身炎症增强相关。
要点
- 发生ICU获得性肌无力的患者(99/204例)在入ICU后前4天IL-6、IL-8、IL-10和fractalkine较未发生者独立升高1.5至2倍。
- 校正疾病严重程度等混杂因素后,主成分1(主要负载IL-6、IL-8、IL-10和fractalkine)与ICU获得性肌无力独立相关(OR 1.35,95%CI 1.18-1.55)。
- 偏最小二乘判别分析同样显示上述标志物是最重要的判别标志物。
- 研究纳入机械通气≥48小时、非神经科入ICU诊断的新入ICU危重患者,ICU获得性肌无力通过患者清醒且注意力集中时手动肌力测试诊断。
适用人群与场景
- 荷兰一家三级医院混合内外科ICU新入院的危重患者,机械通气≥48小时且非神经科入ICU诊断。
诊断标准与关键阈值
- ICU获得性肌无力诊断:患者清醒且注意力集中时通过手动肌力测试诊断。
研究设计与关键结果
- 前瞻性观察性队列研究,纳入204例危重患者,其中99例发生ICU获得性肌无力。
- 入ICU第0、2、4天检测血浆全身炎症标志物及可溶性血管黏附分子。
- 校正混杂因素的主成分回归分析显示,主成分1(主要负载IL-6、IL-8、IL-10和fractalkine)在发生ICU获得性肌无力患者中显著更高(OR 1.35,95%CI 1.18-1.55)。
- 偏最小二乘判别分析显示IL-6、IL-8、IL-10和fractalkine是最重要的判别标志物。
- 混合效应模型显示ICU获得性肌无力与上述标志物独立升高1.5至2倍相关。
证据类型、等级与局限
- 证据类型:前瞻性观察性队列研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,发生ICU获得性肌无力的患者与未发生者相比,在入ICU后前4天全身炎症反应增强,该发现校正疾病严重程度等混杂因素后一致。
- 作者认为,IL-6、IL-8、IL-10和fractalkine组成的标志物组是最重要的判别标志物。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVES: To investigate whether patients who develop ICU-acquired weakness have a different pattern of systemic inflammatory markers compared with critically ill patients who do not develop ICU-acquired weakness.
DESIGN: Prospective observational cohort study.
SETTING: Mixed medical-surgical ICU of a tertiary care hospital in the Netherlands.
PATIENTS: Newly admitted critically ill patients, greater than or equal to 48 hours on mechanical ventilation with a nonneurologic ICU admission diagnosis, were included.
INTERVENTIONS: A panel of systemic inflammatory markers and soluble vascular adhesion molecules were measured in plasma samples of day 0, 2, and 4 after ICU admission. ICU-acquired weakness was diagnosed by manual muscle strength testing as soon as patients were awake and attentive.
MEASUREMENTS AND MAIN RESULTS: Ninety-nine of 204 included patients developed ICU-acquired weakness. Principal component regression analysis, adjusted for confounders, showed that principal component 1, mainly loaded with interleukin-6, interleukin-8, interleukin-10, and fractalkine, was significantly higher in patients who developed ICU-acquired weakness (odds ratio, 1.35 [95% CI, 1.18-1.55]). Partial least squares-discriminant analysis also showed that these markers were the most important discriminative markers. Mixed-effects models of these markers showed that ICU-acquired weakness was associated with an independent 1.5- to two-fold increase in these markers.
CONCLUSIONS: Systemic inflammation is increased in patients who develop ICU-acquired weakness compared with patients who do not develop ICU-acquired weakness in the first 4 days after ICU admission. This finding is consistent when adjusted for confounders, like disease severity. A group consisting of interleukin-6, interleukin-8, interleukin-10, and fractalkine was identified to be the most important.
参考来源
- Witteveen E, Wieske L, van der Poll T, et al. Increased Early Systemic Inflammation in ICU-Acquired Weakness; A Prospective Observational Cohort Study. Crit Care Med. 2017. PMID: 28350642. doi:10.1097/CCM.0000000000002408
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。